CN113508115A - 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病 - Google Patents

吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病 Download PDF

Info

Publication number
CN113508115A
CN113508115A CN202080017509.0A CN202080017509A CN113508115A CN 113508115 A CN113508115 A CN 113508115A CN 202080017509 A CN202080017509 A CN 202080017509A CN 113508115 A CN113508115 A CN 113508115A
Authority
CN
China
Prior art keywords
oxo
amino
isopropyl
pyrimidin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017509.0A
Other languages
English (en)
Chinese (zh)
Inventor
M-G·布劳恩
G·卡斯塔内多
P·吉本斯
J·鲁道夫
W·威尼尔
R·贝弗里奇
W·吴
吴国胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN113508115A publication Critical patent/CN113508115A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080017509.0A 2019-01-03 2020-01-02 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病 Pending CN113508115A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/070275 2019-01-03
CN2019070275 2019-01-03
CNPCT/CN2019/081673 2019-04-08
CN2019081673 2019-04-08
PCT/US2020/012058 WO2020142612A1 (en) 2019-01-03 2020-01-02 Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.

Publications (1)

Publication Number Publication Date
CN113508115A true CN113508115A (zh) 2021-10-15

Family

ID=69400641

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017509.0A Pending CN113508115A (zh) 2019-01-03 2020-01-02 吡啶并嘧啶酮和蝶啶酮化合物作为需要酶i(ire i α)的内切核糖核酸酶肌醇的抑制剂用于治疗癌症疾病

Country Status (6)

Country Link
US (1) US12344603B2 (enExample)
EP (1) EP3941919B1 (enExample)
JP (1) JP7539892B2 (enExample)
CN (1) CN113508115A (enExample)
TW (1) TWI748317B (enExample)
WO (1) WO2020142612A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024131893A1 (en) * 2022-12-22 2024-06-27 Shanghai Yi Zhong Xing Biotechnology Co., Ltd. IRE1α SMALL MOLECULE INHIBITORS

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
JP7611154B2 (ja) * 2019-02-18 2025-01-09 ジェネンテック， インコーポレイテッド ピリド－ピリミジニル化合物及び使用の方法
FI4073065T3 (fi) 2019-12-10 2025-04-16 Hoffmann La Roche Uusia metyylikinatsolinonijohdannaisia
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
EP4263541A1 (en) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG New aryl-pyrido-pyrimidin-one derivatives
WO2022129259A1 (en) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag New quinazolinone derivatives
JP2024523839A (ja) 2021-06-08 2024-07-02 シーフォー セラピューティクス， インコーポレイテッド 突然変異体ｂｒａｆを分解する療法薬
CN115850282A (zh) * 2021-09-24 2023-03-28 华东理工大学 靶向降解egfr蛋白的化合物及其制备方法和应用
PE20250609A1 (es) 2021-12-03 2025-02-26 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos
US12573866B2 (en) 2023-11-17 2026-03-10 Exro Technologies Inc. Battery system for operating point control of power systems

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
KR20020027649A (ko) * 1999-09-15 2002-04-13 로즈 암스트롱, 크리스틴 에이. 트러트웨인 카이나제 억제제로서의 프테리딘온
BR0113628A (pt) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
WO2004063195A1 (en) * 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
JP4758349B2 (ja) * 2003-10-08 2011-08-24 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
CA2570494A1 (en) * 2004-06-23 2006-01-05 Irm Llc Pteridine derivatives as protein kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
EP1846403A1 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
WO2008055842A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
EP2340248B1 (en) 2008-09-15 2017-05-31 The Regents of The University of California Methods and compositions for modulating ire1, src, and abl activity
US9181238B2 (en) * 2010-02-05 2015-11-10 Novartis Ag N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
CA2854462A1 (en) * 2011-11-04 2013-05-10 Afraxis Holdings, Inc. Pak inhibitors for the treatment of fragile x syndrome
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
US20140323478A1 (en) * 2013-04-30 2014-10-30 Afraxis Holdings, Inc. Serine/threonine kinase inhibitors
US20140323477A1 (en) * 2013-04-30 2014-10-30 Genentech, Inc. Serine/threonine kinase inhibitors
CA2911706A1 (en) * 2013-05-09 2014-11-13 Principia Biopharma Inc. Quinolone derivatives as fibroblast growth factor inhibitors
WO2018102751A1 (en) * 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
TW201838981A (zh) 2017-03-17 2018-11-01 美商建南德克公司 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
JP7126084B2 (ja) * 2017-06-01 2022-08-26 コーネル ユニバーシティー Ｉｒｅ１小分子阻害薬
WO2018222917A1 (en) * 2017-06-01 2018-12-06 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors
US10392367B2 (en) 2017-06-01 2019-08-27 Quentis Therapeutics, Inc. IRE1 small molecule inhibitors
TWI831829B (zh) 2018-09-12 2024-02-11 美商建南德克公司 苯氧基-吡啶基-嘧啶化合物及使用方法
JP7546299B2 (ja) 2018-12-03 2024-09-06 コーネル・ユニバーシティー Ｉｒｅ１小分子阻害物質
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
AR118826A1 (es) 2019-05-03 2021-11-03 Kinnate Biopharma Inc Inhibidores de cinasas raf
KR102396930B1 (ko) 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024131893A1 (en) * 2022-12-22 2024-06-27 Shanghai Yi Zhong Xing Biotechnology Co., Ltd. IRE1α SMALL MOLECULE INHIBITORS

Also Published As

Publication number Publication date
EP3941919A1 (en) 2022-01-26
TW202039466A (zh) 2020-11-01
US12344603B2 (en) 2025-07-01
WO2020142612A1 (en) 2020-07-09
EP3941919B1 (en) 2025-12-24
TWI748317B (zh) 2021-12-01
JP2022517189A (ja) 2022-03-07
JP7539892B2 (ja) 2024-08-26
US20230047209A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
US12344603B2 (en) Pyrido-pyrimidinone and pteridinone compounds and methods of use
CN104428299B (zh) 5-氮杂吲唑化合物及其使用方法
JP2024513881A (ja) オキサゼピン化合物及びがんの治療におけるその使用
TWI756636B (zh) 嘧啶并嘧啶化合物及使用方法
CN115996929B (zh) 腺苷A2a受体的拮抗剂
AU2018233402A1 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
US12071425B2 (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
CN116648451A (zh) 拮抗剂化合物
CN116888119A (zh) 腺苷A2a受体的拮抗剂
CN114302877A (zh) 喹唑啉基化合物及使用方法
CN106573927B (zh) 氧杂环庚烷-2-基-吡唑-4-基-杂环基-甲酰胺化合物和使用方法
CN112689528A (zh) 嘧啶基-杂芳氧基-萘基化合物和使用方法
HK40061403A (en) Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases
HK40056588A (en) Pyrido-pyrimidinyl compounds and methods of use
HK40051446A (en) Phenoxy-pyridyl-pyrimidine compounds and methods of use
HK40099028A (zh) 氧氮杂䓬化合物及其在癌症治疗中的用途
HK40062380A (en) Quinazolinyl compounds and methods of use
HK40051987A (en) Pyrimidinyl-heteroaryloxy-naphthyl compounds and methods of use
HK1208439B (zh) 5-氮杂吲唑化合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40061403

Country of ref document: HK